精细TACE的治疗目标与栓塞终点

doi:10.16139/j.1007-9610.2022.02.009

外科理论与实践 ›› 2022, Vol. 27 ›› Issue (02): 131-133.doi: 10.16139/j.1007-9610.2022.02.009

精细TACE的治疗目标与栓塞终点

马婧嶔, 杨敏捷, 颜志平()

复旦大学附属中山医院介入科上海市影像医学研究所国家放射与治疗临床医学研究中心,上海 200032

收稿日期:2022-01-24 出版日期:2022-05-25 发布日期:2022-06-16
通讯作者: 颜志平 E-mail:yan.zhiping@zs
基金资助:
复旦大学附属中山医院青年基金(2020ZSQN77)

Precision transarterial chemoembolization: treatment goal and embolic endpoint

MA Jingqin, YANG Minjie, YAN Zhiping()

Received:2022-01-24 Online:2022-05-25 Published:2022-06-16
Contact: YAN Zhiping E-mail:yan.zhiping@zs

摘要/Abstract

关键词: 经动脉化疗栓塞, 肝细胞癌, 治疗目标, 栓塞终点

中图分类号:

R735.7

马婧嶔, 杨敏捷, 颜志平. 精细TACE的治疗目标与栓塞终点[J]. 外科理论与实践, 2022, 27(02): 131-133.

MA Jingqin, YANG Minjie, YAN Zhiping. Precision transarterial chemoembolization: treatment goal and embolic endpoint[J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 131-133.

参考文献 21

[1]	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249. doi: 10.3322/caac.21660 URL
[2]	Benson AB, D′Angelica MI, Abbott DE, et al. Hepatobi-liary cancers, version 2.2021, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2021, 19(5):541-565. doi: 10.6004/jnccn.2021.0022 URL
[3]	中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗指南(2022年版)[J]. 中国实用外科杂志, 2022, 42(3):241-273.
[4]	马婧嶔, 颜志平. 肝癌介入治疗进一步思考[J]. 介入放射学杂志, 2019, 28(6):507-510.
[5]	张雯, 周永杰, 颜志平. 再论精细TACE[J]. 介入放射学杂志, 2021, 30(10):971-975.
[6]	Kudo M, Han KH, Ye SL, et al. A changing paradigm for the treatment of intermediate-stage hepatocellular carcinoma: Asia-Pacific primary liver cancer expert consensus statements[J]. Liver Cancer, 2020, 9(3):245-260. doi: 10.1159/000507370 URL
[7]	Lencioni R, de Baere T, Soulen MC, et al. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety data[J]. Hepatology, 2016, 64(1):106-116. doi: 10.1002/hep.28453 URL
[8]	Bolondi L, Burroughs A, Dufour JF, et al. Heterogeneity of patients with intermediate (BCLC B) hepatocellular carcinoma: proposal for a subclassification to facilitate treatment decisions[J]. Semin Liver Dis, 2012, 32(4):348-359. doi: 10.1055/s-0032-1329906 pmid: 23397536
[9]	Piscaglia F, Ogasawara S. Patient selection for transarterial chemoembolization in hepatocellular carcinoma: importance of benefit/risk assessment[J]. Liver Cancer, 2018, 7(1):104-119. doi: 10.1159/000485471 pmid: 29662837
[10]	Chang Y, Jeong SW, Jang JY, et al. Recent updates of transarterial chemoembolilzation in hepatocellular carcinoma[J]. Int J Mol Sci, 2020, 21(21):8165. doi: 10.3390/ijms21218165 URL
[11]	Yang K, Sung PS, You YK, et al. Pathologic complete response to chemoembolization improves survival outcomes after curative surgery for hepatocellular carcinoma: predictive factors of response[J]. HPB (Oxford), 2019, 21(12):1718-1726. doi: 10.1016/j.hpb.2019.04.017 URL
[12]	Frenette CT, Osorio RC, Stark J, et al. Conventional TACE and drug-eluting bead TACE as locoregional the-rapy before orthotopic liver transplantation: comparison of explant pathologic response[J]. Transplantation, 2014, 98(7):781-787.
[13]	Sato Y, Watanabe H, Sone M, et al. Tumor response evaluation criteria for HCC (hepatocellular carcinoma) treated using TACE (transcatheter arterial chemoembolization): RECIST (response evaluation criteria in solid tumors) version 1.1 and mRECIST (modified RECIST): JIVROSG-0602[J]. Ups J Med Sci, 2013, 118(1):16-22. doi: 10.3109/03009734.2012.729104 URL
[14]	Bannangkoon K, Hongsakul K, Tubtawee T, et al. Rate and predictive factors for sustained complete response after selective transarterial chemoembolization(TACE) in patients with hepatocellular carcinoma[J]. Asian Pac J Cancer Prev, 2018, 19(12):3545-3550. doi: 10.31557/APJCP.2018.19.12.3545 URL
[15]	Saito N, Tanaka T, Nishiohuku H, et al. Transarterial- chemoembolization remains an effective therapy for intermediate-stage hepatocellular carcinoma with preserved liver function[J]. Hepatol Res, 2020, 50(10):1176-1185. doi: 10.1111/hepr.13550 URL
[16]	Lencioni R, Petruzzi P, Crocetti L. Chemoembolization of hepatocellular carcinoma[J]. Semin Intervent Radiol, 2013, 30(1):3-11. doi: 10.1055/s-0033-1333648 URL
[17]	Terayama N, Matsui O, Gabata T, et al. Accumulation of iodized oil within the nonneoplastic liver adjacent to hepatocellular carcinoma via the drainage routes of the tumor after transcatheter arterial embolization[J]. Car-diovasc Intervent Radiol, 2001, 24(6):383-387.
[18]	Miyayama S. Ultraselective conventional transarterial chemoembolization: when and how?[J]. Clin Mol Hepatol, 2019, 25(4):344-353. doi: 10.3350/cmh.2019.0016 pmid: 31022779
[19]	Miyayama S, Matsui O, Yamashiro M, et al. Ultraselective transcatheter arterial chemoembolization with a 2-f tip microcatheter for small hepatocellular carcinomas: relationship between local tumor recurrence and visualization of the portal vein with iodized oil[J]. J Vasc Interv Radiol, 2007, 18(3):365-376. pmid: 17377182
[20]	Bannangkoon K, Hongsakul K, Tubtawee T, et al. Safety margin of embolized area can reduce local recurrence of hepatocellular carcinoma after superselective transarterial chemoembolization[J]. Clin Mol Hepatol, 2019, 25(1):74-85. doi: 10.3350/cmh.2018.0072 pmid: 30813680
[21]	Miyayama S, Yamashiro M, Ikeda R, et al. Efficacy of superselective conventional transarterial chemoembolization using guidance software for hepatocellular carcinoma within three lesions smaller than 3 cm[J]. Cancers (Basel), 2021, 13(24):6370. doi: 10.3390/cancers13246370 URL

精细TACE的治疗目标与栓塞终点

Precision transarterial chemoembolization: treatment goal and embolic endpoint

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 21

相关文章 15

编辑推荐

Metrics

本文评价

[1]	任新平, 李军建, 张杰, 詹维伟. 超声造影在肝局灶性病变诊疗中的应用进展[J]. 诊断学理论与实践, 2022, 21(06): 684-690.
[2]	孙惠川. 肝细胞癌转化治疗的现状与展望[J]. 外科理论与实践, 2022, 27(02): 134-138.
[3]	张希昊, 章馨允, 曹曼卿, 张金梁, 王华琪, 张苏, 付周, 王鲁, 张倜. 肝细胞癌的抗血管生成免疫联合介入治疗：肝动脉灌注化疗与化疗栓塞疗效的比较[J]. 外科理论与实践, 2022, 27(02): 152-157.
[4]	管涛(综述), 张倜, 王鲁(审校). 肝细胞癌肺转移的潜在机制和治疗进展[J]. 外科理论与实践, 2022, 27(02): 180-184.
[5]	黄纪伟, 邱国腾, 曾勇. 肝细胞癌外科治疗进展[J]. 外科理论与实践, 2022, 27(02): 113-118.
[6]	冯浩, 吕子成, 夏强. 肝癌肝移植全过程管理及治疗进展[J]. 外科理论与实践, 2022, 27(02): 119-122.
[7]	吴城孝, 方婕, 周霁川, 肖永胜, 张晓光. 基于TCGA数据库肝细胞癌microRNA-324-5p表达与预后危险因素分析[J]. 外科理论与实践, 2021, 26(03): 249-253.
[8]	张勇强, 张倜, 孔银龙, 侯振宇, 李慧锴, 崔云龙, 宋天强, 李强. 术中出血对早期肝细胞癌病人围术期及预后的影响[J]. 外科理论与实践, 2018, 23(04): 342-345.
[9]	侯振宇, 孔银龙, 张勇强, 朱科云, 杨雪娇, 陈平, 李慧锴, 崔云龙, 宋天强, 李强, 张倜. 术前白细胞计数预测肝切除治疗超“米兰标准”肝细胞癌病人的预后[J]. 外科理论与实践, 2018, 23(04): 358-362.
[10]	肖永胜, 周俭. 非酒精性脂肪性肝病与肝细胞癌[J]. 外科理论与实践, 2018, 23(03): 210-213.
[11]	佟辉, 张家强, 祝哲诚, 彭承宏, 李涛. 超“UCSF标准”肝细胞癌肝移植术前经肝动脉化疗栓塞的疗效[J]. 外科理论与实践, 2018, 23(03): 241-246.
[12]	高志慧, 柏斗胜. 精准医学时代肝细胞癌破裂出血的诊治[J]. 外科理论与实践, 2018, 23(03): 217-220.
[13]	李涛, 祝哲诚, 彭承宏. 肝移植“精准”治疗原发性肝脏恶性肿瘤[J]. 外科理论与实践, 2018, 23(03): 200-204.
[14]	周恺乾, 周成, 王征. 肝异型增生结节的研究进展[J]. 外科理论与实践, 2018, 23(03): 286-288.
[15]	祝桂琦, 王彪, 杨怡, 代智. γδT细胞在肝细胞癌中作用的研究进展[J]. 外科理论与实践, 2018, 23(03): 289-292.